close

Cypress Bioscience, Inc. provides therapeutics and personalized medicine services. The company focuses on addressing the needs of physicians and their patients by identifying unmet medical needs in the areas of pain, rheumatology, and physical medicine and rehabilitation, including challenging disorders, such as fibromyalgia and rheumatoid arthritis. It offers Savella, a dual-reuptake inhibitor that preferentially blocks the reuptake of norepinephrine for the management of fibromyalgia. The company provides personalized medicine services, which include tests that are validated analytically and clinically to provide physicians with actionable information to help manage their patientsÂ’ care, including predicting the likelihood of developing disease or optimizing therapy. Its personalized medicine services include Avise PG, a test that supports dose optimization and therapeutic decision making for patients taking methotrexate, a therapy for rheumatoid arthritis (RA); and Avise MCV, a test that aids in the diagnosis and prognosis of RA. The company has a license agreement with Pierre Fabre Medicament to develop and sell products with the compound milnacipran as an active ingredient for various indications in the United States and Canada; a collaboration agreement with Forest Laboratories, Inc. for the development and marketing of milnacipran; and a reformulation and new product agreement with Collegium Pharmaceutical, Inc. Cypress Bioscience, Inc. was founded in 1981 and is based in San Diego, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	6.50
Volume	140781
Volume Avg	713980
52 Week High	6.55
52 Week Low	2.06
PE	N/A
PE (group average)	39
EPS Year	-1.36
EPS change Q/Q	-58.33%
EPS change Q/Q Yr ago	-78.26%
EPS change Q/Q next Q est	0%
EPS change Y/Y	-75%
REV change Q/Q	12.35%
REV change Q/Q Yr ago	56.9%
EPS next Q est	-0.05
EPS next Y est	-0.13
Divident Annual	0.00
Dividend Yield	0%